The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Nicotinic ACh receptors as therapeutic targets in CNS disorders
Open accessAbstract
The neurotransmitter acetylcholine (ACh) can regulate neuronal excitability by acting on the cys-loop cation-conducting ligand-gated nicotinic ACh receptor channels (nAChRs). These receptors are widely distributed throughout the central nervous system, being expressed on neurons and non-neuronal cells, where they participate in a variety of physiological responses such as anxiety, the central processing of pain, food intake, nicotine seeking behavior, and cognitive functions. In the mammalian brain, nine different subunits have been found thus far, which assemble into pentameric complexes with much subunit diversity; however the α7 and α4β2 subtypes predominate in the CNS. Neuronal nAChR dysfunction is involved in the pathophysiology of many neurological disorders. Here we will briefly discuss the functional makeup and expression of the nAChRs in the mammalian brain, and their role as targets in neurodegenerative diseases (in particular Alzheimer’s disease), neurodevelopmental disorders (in particular autism and schizophrenia), and neuropathic pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“memory function for the stage of AD pathology seen with currently accepted biomarkers for AD staging [86, 87]).”
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation
Wang, H., Yu, M., Ochani, M., Amella, C. A., Tanovic, M., Susarla, S., Li, J. H., Wang, H., Yang, H., Ulloa, L., et al. (2003) · Nature · doi:10.1038/nature01339 · Cited by 3,228
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Presynaptic nicotinic ACh receptors
Wonnacott, S. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10073-4 · Cited by 1,308
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus
Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141
Brain nicotinic acetylcholine receptors: native subtypes and their relevance
Gotti, C., Zoli, M., & Clementi, F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.004 · Cited by 882
Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus
Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2692-08.2008 · Cited by 740
Activity-dependent neuronal signalling and autism spectrum disorder
Ebert, D. H., & Greenberg, M. E. (2013) · Nature · doi:10.1038/nature11860 · Cited by 666
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Rethinking inflammation: neural circuits in the regulation of immunity
Olofsson, P. S., Rosas‐Ballina, M., Levine, Y. A., & Tracey, K. J. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01138.x · Cited by 393 · cited 1×
“Immune cell expression of α7* receptors has been shown to modulate inflammatory responses by regulating the production of inflammatory cytokines and chemokines [33, 34].”
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303
Dineley, K. T., Xia, X., Bui, D., Sweatt, J. D., & Zheng, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200164200 · Cited by 212 · cited 1×
“This model is supported by reports that α7* nAChRs are upregulated in several AD patient cell types, including astrocytes and neurons [93–96], as well as in AD animal models [97], and neuronal cell cultures chronically exposed to Aβ [98].”
Self-citationNeuronal nicotinic receptors: A perspective on two decades of drug discovery research
Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208
Fenster, C. P., Whitworth, T. L., Sheffield, E. B., Quick, M. W., & Lester, R. A. J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-04804.1999 · Cited by 204
Teaktong, T., Graham, A., Court, J., Perry, R., Jaros, E., Johnson, M., Hall, R., & Perry, E. (2003) · Glia · doi:10.1002/glia.10132 · Cited by 151
Molecular analysis of nicotinic receptor expression in autism
Martin-Ruiz, C. M., Lee, M., Perry, R. H., Baumann, M., Court, J. A., & Perry, E. K. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.01.003 · Cited by 141
Pirttimaki, T. M., Codadu, N. K., Awni, A., Pratik, P., Nagel, D. A., Hill, E. J., Dineley, K. T., & Parri, H. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081828 · Cited by 103
Self-citationDeutsch, S. I., Urbano, M. R., Neumann, S. A., Burket, J. A., & Katz, E. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181d6f7ad · Cited by 99
Bell, K. A., Shim, H., Chen, C.-K., & McQuiston, A. R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.024 · Cited by 74
Nicotinic cholinergic antagonists: A novel approach for the treatment of autism
Lippiello, P. M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.11.015 · Cited by 43
Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders
Arnold, L. E., Aman, M. G., Hollway, J., Hurt, E., Bates, B., Li, X., Farmer, C., Anand, R., Thompson, S., Ramadan, Y., et al. (2012) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0056 · Cited by 42
Cited by
NACHO Mediates Nicotinic Acetylcholine Receptor Function throughout the Brain
Matta, J. A., Gu, S., Davini, W. B., Lord, B., Siuda, E. R., Harrington, A. W., & Bredt, D. S. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.04.008 · Cited by 88
Getting a Handle on Neuropharmacology by Targeting Receptor-Associated Proteins
Maher, M. P., Matta, J. A., Gu, S., Seierstad, M., & Bredt, D. S. (2017) · Neuron · doi:10.1016/j.neuron.2017.10.001 · Cited by 64
Xu, Z.-Q., Zhang, W.-J., Su, D.-F., Zhang, G.-Q., & Miao, C.-Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-273 · Cited by 60
Sinha, N., Karche, N. P., Verma, M. K., Walunj, S. S., Nigade, P. B., Jana, G., Kurhade, S. P., Hajare, A. K., Tilekar, A. R., Jadhav, G. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01569 · Cited by 30
Zhao, J., Zhang, R., Wang, W., Jiang, S., Liang, H., Guo, C., Qi, J., Zeng, H., & Song, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109880 · Cited by 25
Metadata
- Authors
- Dineley, K. T., Pandya, A. A., & Yakel, J. L.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 36
- Issue
- 2
- Pages
- 96-108
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2010022125
- Cited by
- 450
- References
- 23
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
